Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
In: Molecular Metabolism, 49, S.

Event
Veröffentlichung
(where)
Augsburg
(who)
Universität Augsburg
(when)
2021
Event
Veröffentlichung
(who)
Elsevier BV
(when)
2021
Creator
Novikoff, Aaron
O'Brien, Shannon L.
Bernecker, Miriam
Grandl, Gerald
Kleinert, Maximilian
Knerr, Patrick J.
Stemmer, Kerstin
Klingenspor, Martin
Zeigerer, Anja
DiMarchi, Richard
Tschöp, Matthias H.
Finan, Brian
Calebiro, Davide
Müller, Timo D.

DOI
10.1016/j.molmet.2021.101181
URN
urn:nbn:de:bvb:384-opus4-899960
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Novikoff, Aaron
  • O'Brien, Shannon L.
  • Bernecker, Miriam
  • Grandl, Gerald
  • Kleinert, Maximilian
  • Knerr, Patrick J.
  • Stemmer, Kerstin
  • Klingenspor, Martin
  • Zeigerer, Anja
  • DiMarchi, Richard
  • Tschöp, Matthias H.
  • Finan, Brian
  • Calebiro, Davide
  • Müller, Timo D.
  • Universität Augsburg
  • Elsevier BV

Time of origin

  • 2021

Other Objects (12)

Spatiotemporal GLP-1 and GIP Receptor Signaling and Trafficking/Recycling Dynamics Induced by Selected Receptor Mono- and Dual-agonists

Spatiotemporal GLP-1 and GIP Receptor Signaling and Trafficking/Recycling Dynamics Induced by Selected Receptor Mono- and Dual-agonists

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?

GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers

GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers

Effects of GLP-1 receptor agonists on neurological complications of diabetes

Effects of GLP-1 receptor agonists on neurological complications of diabetes

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?

ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?

ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Potential implications of long-acting GLP-1 receptor agonists for critically ill

Potential implications of long-acting GLP-1 receptor agonists for critically ill

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications

Related objects